CeriBell, Inc. (NASDAQ:CBLL) Given Consensus Recommendation of "Buy" by Analysts

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) has received an average rating of "Buy" from the seven analysts that are presently covering the company, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have covered the stock in the last year is $32.50.

A number of research firms have issued reports on CBLL. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 target price on shares of CeriBell in a research note on Wednesday, February 26th. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research note on Friday, April 4th. They issued a "buy" rating and a $32.00 target price for the company.

Insiders Place Their Bets

In other CeriBell news, CEO Xingjuan Chao sold 5,700 shares of the company's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $15.02, for a total transaction of $85,614.00. Following the completion of the sale, the chief executive officer now directly owns 746,451 shares in the company, valued at $11,211,694.02. This represents a 0.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Rebecca B. Robertson sold 11,188 shares of the company's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $17.85, for a total transaction of $199,705.80. Following the sale, the director now owns 10,042 shares of the company's stock, valued at $179,249.70. This trade represents a 52.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 113,333 shares of company stock valued at $1,895,195 over the last three months. 20.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On CeriBell

A number of hedge funds have recently bought and sold shares of the company. FMR LLC bought a new stake in CeriBell during the fourth quarter valued at about $128,120,000. TPG GP A LLC bought a new stake in CeriBell during the fourth quarter valued at about $102,677,000. Red Tree Management LLC bought a new stake in CeriBell during the fourth quarter valued at about $57,083,000. Yu Fan bought a new stake in CeriBell during the fourth quarter valued at about $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd bought a new stake in CeriBell during the fourth quarter valued at about $28,160,000.

CeriBell Stock Performance

CBLL traded up $0.11 during trading on Wednesday, reaching $17.91. 254,336 shares of the stock traded hands, compared to its average volume of 282,197. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.36 and a quick ratio of 16.81. CeriBell has a fifty-two week low of $10.01 and a fifty-two week high of $32.75. The stock's 50-day simple moving average is $16.67 and its two-hundred day simple moving average is $20.69.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. The firm had revenue of $20.49 million for the quarter, compared to analyst estimates of $19.30 million. Equities research analysts anticipate that CeriBell will post -2.46 EPS for the current year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.